Showing 2271-2280 of 2494 results for "".
- US Patents for Nicox’s Vyzulta (Latanoprostene Bunod) Eligible for Patent Term Extensionhttps://modernod.com/news/us-patents-for-nicoxs-vyzulta-latanoprostene-bunod-eligible-for-patent-term-extension/2479103/Nicox SA announced that the United States Patent and Trademark Office (USPTO) has determined that three U.S. composition of matter patents covering latanoprostene bunod, commercialized as Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, are eligible for patent term extension, potential
- Feds Call Halt to Johnson & Johnson COVID-19 Vaccine Rollout After ‘Extremely Rare’ Blood Clot Caseshttps://modernod.com/news/feds-call-halt-to-johnson-johnson-covid-19-vaccine-rollout-after-extremely-rare-blood-clot-cases/2479070/After drug regulators on both sides of the Atlantic revealed safety probes into Johnson & Johnson’s COVID-19 vaccine, U.S. officials are calling fo
- Computer Model Fosters Potential Improvements to ‘Bionic Eye’ Technologyhttps://modernod.com/news/computer-model-fosters-potential-improvements-to-bionic-eye-technology/2479063/There are millions of people who face the loss of their eyesight from degenerative eye diseases. The genetic disorder retinitis pigmentosa alone affects 1 in 4,000 people worldwide. Today, there is technology available to offer partial eyesight to people with that syndrome. The Argus II, the worl
- FDA Approves Bausch + Lomb ClearVisc Dispersive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/fda-approves-bausch-lomb-clearvisc-dispersive-ophthalmic-viscosurgical-device-ovd/2479058/Bausch + Lomb, announced that the FDA has approved ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. “OVDs play a critical role in ophthalmic surgery, and ClearVisc offers surgeons unique advantages that are designed to contribute to surgical safety
- Large Employers are Eyeing On-Site COVID-19 Vaccines, Survey Showshttps://modernod.com/news/large-employers-are-eyeing-on-site-covid-19-vaccines-survey-shows/2479044/Many large employers are expecting to offer COVID-19 vaccines on-site for workers by the end of the year, a new survey shows, according to a Fierce Healthcare
- Eyenovia Announces Appointment of Julia Haller, MD, to its Board of Directorshttps://modernod.com/news/eyenovia-announces-appointment-of-julia-haller-md-to-its-board-of-directors/2479041/Eyenovia announced the appointment of Julia Haller, MD, to its Board of Directors. “We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” Sean Ianchulev, MD, PhD, Chief Executive Officer and Chief Medical
- CorneaGen Names Bernie Iliakis Presidenthttps://modernod.com/news/corneagen-names-bernie-iliakis-president/2478979/CorneaGen announced that Bernardino “Bernie” Iliakis has been promoted from chief operating officer to president of the company. Mr. Iliakis will assume leadership of the company as part of Monty Montoya’s transition from CEO to strategic advisor to CorneaGen.
- New iCare HOME2 Self-Tonometer Enables Eye Pressure Measurement by Glaucoma Patientshttps://modernod.com/news/new-icare-home2-self-tonometer-enables-accurate-eye-pressure-measurement-by-glaucoma-patients/2478976/Icare Finland is launching their next generation self-tonometer, the iCare HOME2. iCare HOME2 provides ease of use and accuracy in monitoring real-world IOP behavior outside of the doctor’s office and clinical hours, supporting glaucoma management, according to a company news release
- J&J’s Coronavirus Vaccine Garners WHO Emergency-Use Listinghttps://modernod.com/news/jjs-coronavirus-vaccine-garners-who-emergency-use-listing/2478968/Johnson & Johnson said that the World Health Organization (WHO) has issued an emergency-use listing for its single-dose coronavirus vaccine Ad26.COV2.S to prevent COVID-19 in people 18 years and older. Chief scientific officer Paul Stoffels stated that “achieving this important prerequi
- Bausch Health Announces CFO Succession Planhttps://modernod.com/news/bausch-health-announces-cfo-succession-plan/2478964/Bausch Health Companies announced that Paul S. Herendeen will be succeeded as Chief Financial Officer (CFO) by Sam Eldessouky, senior vice president, controller and chief accounting officer of Bausch Health. Mr. Herendeen is being appointed to the newly created role of Advisor to the chai